home / stock / crpof / crpof articles
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro ...
News, Short Squeeze, Breakout and More Instantly...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...
– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pi...